Aim: To compare the effects of AMP579 and adenosine on L-type Ca 2+ current (I Ca-L ) in rat ventricular myocytes and explore the mechanism by which AMP579 acts on I Ca-L . Methods: I Ca-L was recorded by patch-clamp technique in whole-cell configuration. Results: Adenosine (10 nmol/L to 50 µmol/L) showed no effect on basal I Ca-L , but it inhibited the I Ca-L induced by isoproterenol 10 nmol/L in a concentration-dependent manner with the IC 50 of 13.06 µmol/L. Similar to adenosine, AMP579 also showed an inhibitory effect on the I Ca-L induced by isoproterenol. AMP579 and adenosine (both in 10 µmol/L) suppressed isoproterenol-induced I Ca-L by 11.1% and 5.2%, respectively. In addition, AMP579 had a direct inhibitory effect on basal I Ca-L in a concentration-dependent manner with IC 50 (1.17 µmol/L). PD116948 (30 µmol/L), an adenosine A 1 receptor blocker, showed no action on the inhibitory effect of AMP579 on basal I Ca-L . However, GF109203X (0.4 µmol/L), a special protein kinase C (PKC) blocker, could abolish the inhibitory effect of AMP579 on basal I Ca-L . So the inhibitory effect of AMP579 on basal I Ca-L was induced through activating PKC, but not linked to adenosine A 1 receptor. Conclusion: AMP579 shows a stronger inhibitory effect than adenosine on the I Ca-L induced by isoproterenol. AMP579 also has a strong inhibitory effect on basal I Ca-L in rat ventricular myocytes. Activation of PKC is involved in the inhibitory effect of AMP579 on basal I Ca-L at downstream-mechanism. Recent studies showed that AMP579 was a novel adenosine agonist with high affinity for adenosine A 1 and A 2 receptors [1, 2] . Experiments in animal models have demonstrated that AMP579 reduced infarct size by 50% to 98% when administered before a final ischemic event (mediation of ischemic preconditioning) or just before reperfusion (attenuation of reperfusion injury) [3, 4] . Further experiments on pigs, dogs, and rabbits suggested that AMP579 was more powerful than adenosine in attenuating polymorphonuclear neutrophil-mediated inflammatory responses, dilating the coronary artery, reducing myocardial contracture and limiting infarct size [5, 6] . Although the protective effect of AMP579 required adenosine receptor activation, adenosine could not duplicate the effects.
Recent studies showed that AMP579 was a novel adenosine agonist with high affinity for adenosine A 1 and A 2 receptors [1, 2] . Experiments in animal models have demonstrated that AMP579 reduced infarct size by 50% to 98% when administered before a final ischemic event (mediation of ischemic preconditioning) or just before reperfusion (attenuation of reperfusion injury) [3, 4] . Further experiments on pigs, dogs, and rabbits suggested that AMP579 was more powerful than adenosine in attenuating polymorphonuclear neutrophil-mediated inflammatory responses, dilating the coronary artery, reducing myocardial contracture and limiting infarct size [5, 6] . Although the protective effect of AMP579 required adenosine receptor activation, adenosine could not duplicate the effects.
The difference between pharmacologic effect of AMP579 and adenosine might reflect the differences in ionic mechanisms. It has been established that adenosine could cause an attenuation of basal I Ca-L only in unstimulated atrial myocytes, but under conditions of isoproterenol stimulation, adenosine could markedly attenuate isoproterenol induced-I Ca-L in both atrial and ventricular myocytes. However, little is known about the electrophysiological effects of AMP579 so far. This study will examine the effects of AMP579 and adenosine on L-type calcium channel and elucidate theIntroduction isolation procedure. In brief, rats were killed by cervical dislocation and the heart was then immediately removed, cannulated through the aorta and perfused through the coronary artery with Ca The calcium current was expressed as membrane current density (pA/pF). The cell capacitance was measured by the method previously described by Coetzee et al [9] . I Ca-L was measured according to the method described by Hartzell et al [10] . The AMP579 was a gift from Department of Cardiothoracic Surgery Research Laboratory, Emory University School of Medicine, USA. AMP579 was dissolved in small volumes of Me 2 SO, then diluted to the desired final concentration before each experiment.
Statistic analysis Data were expressed as mean±SD. Statistical significance was determined by Student's t-test and P<0.05 was considered significant.
Results

Detection of L-type calcium channel current
The calcium current was activated by depolarizing pulse from a holding potential of -40 mV to +10 mV at 50 mV step-voltage. This inward current could be completely inhibited by 1 µmol/L verapmil, the basic characteristics indicated that the current present in rat ventricular myocytes was L-type Ca 2+ current . Effect of AMP579 and adenosine on L-type calcium current In the presence of adenosine at 10 nmol/L, 1, 10, and 50 µmol/L, I Ca-L varied from 4.9±0.9 to 4.8±0.9, 4.9±0.9, 4.9±0.9, 4.7±0.9 pA/pF, respectively (n=5, P>0.05). Adenosine had no effect on basal I Ca-L . However, when I Ca-L was augmented to 2.7±0.6 pA/pF by 10 nmol/L isoproterenol, adenosine at 10 nmol/L, 1, 10, and 50 µmol/L significantly reduced it to 2.4±0.6, 2.1±0.6, 2.0±0.5, and 1.9±0.5 pA/pF, respectively (n=4, P<0.05). Adenosine showed an inhibitory effect on isoproterenol-induced I Ca-L in a concentration-dependent manner with the IC 50 of 13.06 µmol/L (Figure 1, 2) .
Effect of AMP579 on I Ca-L Isoproterenol 10 nmol/L augmented I Ca-L to 3.8±0.7 pA/pF. AMP579 10 µmol/L reduced I Ca-L to 2.4±0.1 pA/pF (P<0.05, n=3, Figure 3) , AMP579 also showed an inhibitory effect on isoproterenol-induced I Ca-L . AMP579 and adenosine (both 10 µmol/L) suppressed isoproterenol-induced I Ca-L by 11.1% and 5.2%, respectively. AMP579 had a stronger inhibitory effect. In contrast to adenosine, AMP579 possessed a direct inhibitory effect on basal I Ca-L in a concentration-dependent manner with the IC 50 of 1.17 µmol/L (Table 1, Figure 4 Change rate=(the current value after administration of drug−control value)/control value×100% 
Discussion
In cardiac tissue, a direct inhibition of basal I Ca-L by adenosine has only been demonstrated in guinea-pig atrial and ferret ventricular myocytes [11, 12] . But in the presence of isoproterenol stimulation, adenosine has prominent inhibitory effects on I Ca-L in ventricular myocytes [13] . These may reflect differences in receptor-effector coupling mechanisms, the level of basal adenylate cyclase activity, the basal phosphorylated state of Ca 2+ channels and/or the effect of phosphorylation on the gating of L-type Ca 2+ channel. Consistent with previous reports, our experiment shows that adenosine has no direct inhibitory effect on basal I Ca-L in the rat ventricle, but in the condition that isoproterenol was previously administered, adenosine shows an inhibitory effect on the I Ca-L induced by isoproterenol with an IC 50 of 13.06 µmol/L, suggesting that adenosine exerts an indirect inhibitory effect on I Ca-L in the rat ventricle by inhibition of isoproterenol stimulation.
In contrast to adenosine, AMP579 shows a direct inhibitory effects on basal I Ca-L in the rat ventricle with IC 50 of 1.17 µmol/L. The blocking of Ca 2+ influx by L-type Ca 2+ channel could serve as an efficient method for protecting the ischemic myocyte by minimizing ischemia-induced Ca 2+ overload and irreversible cell contracture and autodigestion by Ca 2+ -dependent proteases [14] . Therefore, by reducing both basal I Ca-L and isoproterenol-induced I Ca-L, AMP579 will play a more important role in negative chronotropic and negative dromotropic effects. These action mechanism differences between AMP579 and adenosine may account for the contribution of AMP579 in reducing neutrophil-mediated inflammatory reaction, inhibiting cardiac contraction, dilating coronary vessels, attenuating ischemia and reperfusion injury.
Our study does not show that adenosine A 1 receptor is linked to inhibition of AMP579 on basal I Ca-L . At present, available data indicate that three pathways are involved in receptor-linked downstream mechanisms for inhibition of I Ca-L by adenosine. The first is cAMP-PKA, as PKA increase I Ca-L by phosphorylation on the gating of the L-type calcium channel, inhibitions of adenylate cyclase and reductions of cAMP and PKA levels by adenosine result in attenuation on I Ca-L [12] . Second is that activation of guanylate cyclase results in increments of intracellular cGMP and PKG concentration, which in turn inhibits phosphorylation on the gating of the L-type calcium channel [15] . The third is modulated by PKC, because there are different PKC subunits which result in different effects [16] . Our experiment finds that special PKC antagonist GF109203X can totally eliminate inhibitory effects of AMP579 on I Ca-L , suggesting that AMP579 exerts a direct inhibitory effects on the L-type calcium channel through the PKC pathway.
